JP2023523096A5 - - Google Patents

Info

Publication number
JP2023523096A5
JP2023523096A5 JP2023506362A JP2023506362A JP2023523096A5 JP 2023523096 A5 JP2023523096 A5 JP 2023523096A5 JP 2023506362 A JP2023506362 A JP 2023506362A JP 2023506362 A JP2023506362 A JP 2023506362A JP 2023523096 A5 JP2023523096 A5 JP 2023523096A5
Authority
JP
Japan
Prior art keywords
amino acid
approximately
acid sequence
sequence seq
containing amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023506362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/050544 external-priority patent/WO2021212222A1/en
Publication of JP2023523096A publication Critical patent/JP2023523096A/ja
Publication of JP2023523096A5 publication Critical patent/JP2023523096A5/ja
Pending legal-status Critical Current

Links

JP2023506362A 2020-04-20 2021-04-20 急性呼吸促迫症候群を治療するための組成物および方法 Pending JP2023523096A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063012783P 2020-04-20 2020-04-20
US202063012786P 2020-04-20 2020-04-20
US63/012,783 2020-04-20
US63/012,786 2020-04-20
US202063081662P 2020-09-22 2020-09-22
US63/081,662 2020-09-22
PCT/CA2021/050544 WO2021212222A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Publications (2)

Publication Number Publication Date
JP2023523096A JP2023523096A (ja) 2023-06-01
JP2023523096A5 true JP2023523096A5 (cg-RX-API-DMAC10.html) 2024-04-25

Family

ID=78270861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506362A Pending JP2023523096A (ja) 2020-04-20 2021-04-20 急性呼吸促迫症候群を治療するための組成物および方法

Country Status (8)

Country Link
US (1) US20230192881A1 (cg-RX-API-DMAC10.html)
EP (1) EP4138912A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023523096A (cg-RX-API-DMAC10.html)
CN (1) CN115697410A (cg-RX-API-DMAC10.html)
AU (1) AU2021261060A1 (cg-RX-API-DMAC10.html)
CA (1) CA3174429A1 (cg-RX-API-DMAC10.html)
IL (1) IL297363A (cg-RX-API-DMAC10.html)
WO (1) WO2021212222A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12165313B2 (en) * 2019-01-14 2024-12-10 Ark Inc. Deep learning architecture system for automatic fundus image reading and automatic fundus image reading method using deep learning architecture system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
SI2173381T1 (sl) * 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
JP6289098B2 (ja) * 2011-01-10 2018-03-07 ノビミューン エスアー 抗tlr4抗体およびその使用法
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
EP3060250A1 (en) * 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
WO2017021552A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
EP3519049B1 (en) * 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody

Similar Documents

Publication Publication Date Title
JP2023515271A5 (cg-RX-API-DMAC10.html)
JP2020518599A5 (cg-RX-API-DMAC10.html)
JP2004534513A5 (cg-RX-API-DMAC10.html)
JP2022531205A5 (cg-RX-API-DMAC10.html)
JP2024518536A5 (cg-RX-API-DMAC10.html)
JP2022535523A5 (cg-RX-API-DMAC10.html)
JP2025511167A5 (cg-RX-API-DMAC10.html)
CN111163792A (zh) 用于治疗病毒感染的肽
JP2025176030A (ja) ウイルス起源の各感染症の治療のためのペプチド
JP2024177399A (ja) 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
EP4655001A1 (en) Method for prevention or treatment of coronavirus infection
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
JP2023526853A5 (cg-RX-API-DMAC10.html)
EP4107186A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
JP2022553703A5 (cg-RX-API-DMAC10.html)
KR20250148609A (ko) 코로나바이러스 감염의 예방 또는 치료 방법
KR20250148604A (ko) 코로나바이러스 감염의 예방 또는 치료 방법
KR20250148605A (ko) 코로나바이러스 감염의 예방 또는 치료 방법
EP4655003A1 (en) Method for prevention or treatment of coronavirus infection
JP2023518815A (ja) Il6アンタゴニストによるcovid-19肺炎を含む肺炎の治療方法
JP2023538369A5 (cg-RX-API-DMAC10.html)